Here's how DOI.ORG makes money* and how much!

*Please read our disclaimer before using our estimates.
Loading...

DOI . ORG {}

  1. Analyzed Page
  2. Matching Content Categories
  3. CMS
  4. Monthly Traffic Estimate
  5. How Does Doi.org Make Money
  6. Keywords
  7. Topics
  8. Questions
  9. Schema
  10. External Links
  11. Analytics And Tracking
  12. Libraries
  13. Hosting Providers
  14. CDN Services

We began analyzing https://link.springer.com/article/10.1007/s40265-024-02061-0, but it redirected us to https://link.springer.com/article/10.1007/s40265-024-02061-0. The analysis below is for the second page.

Title[redir]:
Prevention of Rheumatoid Arthritis in At-Risk Individuals: Current Status and Future Prospects | Drugs
Description:
Early intervention has been the cornerstone of improving outcomes in patients with rheumatoid arthritis. Over the past decade, the boundaries have been pushed in an attempt to achieve effective prevention strategies in those who are at high risk of developing rheumatoid arthritis. Core risk factors including the presence of serum anti-citrullinated protein antibodies, arthralgia and subclinical inflammation on imaging are highly predictive of arthritis development. The influence of air pollution, diet and the role of microbiome on disease progression are less clear. In turn, therapeutic focus has shifted to an earlier pre-arthritis phase of the disease continuum where the clinically apparent arthritis may potentially be intercepted. Seven proof-of-concept interventional trials in at-risk individuals have been conducted so far. Whether true prevention of rheumatoid arthritis is possible remains elusive. Promising signals towards permanent disease modulation and improvement in symptom burden were seen with some immunomodulatory therapies, whilst others were unsuccessful. Long-term follow-up is required to ascertain a true effect. Looking forward, a better understanding of the natural history and underlying biological mechanisms of arthritis development and more accurate, validated risk stratification is needed.

Matching Content Categories {📚}

  • Health & Fitness
  • Education
  • Science

Content Management System {📝}

What CMS is doi.org built with?

Custom-built

No common CMS systems were detected on Doi.org, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of doi.org audience?

🏙️ Massive Traffic: 50M - 100M visitors per month


Based on our best estimate, this website will receive around 98,426,998 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Doi.org Make Money? {💸}

We see no obvious way the site makes money.

Earning money isn't the goal of every website; some are designed to offer support or promote social causes. People have different reasons for creating websites. This might be one such reason. Doi.org might be plotting its profit, but the way they're doing it isn't detectable yet.

Keywords {🔍}

arthritis, pubmed, article, google, scholar, rheumatoid, cas, risk, rheum, central, ann, dis, van, individuals, patients, development, rheumatol, httpsdoiorgs, study, httpsdoiorgannrheumdis, arthralgia, mankia, disease, httpsdoiorgart, trial, httpsdoiorgard, rheumatism, early, factors, palindromic, prevention, treatment, open, res, atrisk, developing, antibodies, progression, systematic, review, clinical, content, data, high, protein, inflammation, rmd, httpsdoiorgrmdopen, lancet, doubleblind,

Topics {✒️}

month download article/chapter van der veer-meerkerk population-based case-control study anti-carbamylated protein antibodies van steenbergen hw anti-ccp positive individuals anti-ccp-positive individuals van dijk bt smolen js b-cell directed therapy sugar-sweetened soda consumption long-term dietary quality t-cell costimulation modulation earlier pre-arthritis phase murine collagen-induced arthritis pre-rheumatoid arthritis condition anti-ccp-positive gillet-van dongen article drugs aims article toyoda full article pdf cyclic citrullinated peptide mri-detected subclinical inflammation dose-response meta-analysis citrullinated protein antigens citrullinated-protein-antigens international task force recent-onset rheumatoid arthritis de jong ba kulveer mankia connective tissue diseases van baarsen lg privacy choices/manage cookies anticitrullinated peptide antibodies trigger hla-dr musculoskeletal medicine deane kd gomez-puerta ja offered preventive treatment lancet healthy longev permanent disease modulation bos wh tight control strategy grant support—gilead systematic literature search van boheemen factors predicting response accepted manuscript version rheumatology/european league prospective cohort study

Questions {❓}

  • Does periodontal treatment improve rheumatoid arthritis disease activity?
  • How should we treat palindromic rheumatism?
  • Is air pollution a risk factor for rheumatoid arthritis?
  • Is palindromic rheumatism a pre-rheumatoid arthritis condition?
  • Rheumatoid arthritis prevention in arthralgia: fantasy or reality?
  • What is the evidence for the presence of a therapeutic window of opportunity in rheumatoid arthritis?
  • When and how should we use imaging in individuals at risk of rheumatoid arthritis?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Prevention of Rheumatoid Arthritis in At-Risk Individuals: Current Status and Future Prospects
         description:Early intervention has been the cornerstone of improving outcomes in patients with rheumatoid arthritis. Over the past decade, the boundaries have been pushed in an attempt to achieve effective prevention strategies in those who are at high risk of developing rheumatoid arthritis. Core risk factors including the presence of serum anti-citrullinated protein antibodies, arthralgia and subclinical inflammation on imaging are highly predictive of arthritis development. The influence of air pollution, diet and the role of microbiome on disease progression are less clear. In turn, therapeutic focus has shifted to an earlier pre-arthritis phase of the disease continuum where the clinically apparent arthritis may potentially be intercepted. Seven proof-of-concept interventional trials in at-risk individuals have been conducted so far. Whether true prevention of rheumatoid arthritis is possible remains elusive. Promising signals towards permanent disease modulation and improvement in symptom burden were seen with some immunomodulatory therapies, whilst others were unsuccessful. Long-term follow-up is required to ascertain a true effect. Looking forward, a better understanding of the natural history and underlying biological mechanisms of arthritis development and more accurate, validated risk stratification is needed.
         datePublished:2024-07-02T00:00:00Z
         dateModified:2024-07-02T00:00:00Z
         pageStart:895
         pageEnd:907
         sameAs:https://doi.org/10.1007/s40265-024-02061-0
         keywords:
            Pharmacotherapy
            Pharmacology/Toxicology
            Internal Medicine
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs40265-024-02061-0/MediaObjects/40265_2024_2061_Fig1_HTML.png
         isPartOf:
            name:Drugs
            issn:
               1179-1950
               0012-6667
            volumeNumber:84
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer International Publishing
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Task Toyoda
               url:http://orcid.org/0000-0001-5784-9281
               affiliation:
                     name:University of Leeds
                     address:
                        name:Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK
                        type:PostalAddress
                     type:Organization
                     name:Leeds Teaching Hospitals NHS Trust
                     address:
                        name:NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Kulveer Mankia
               affiliation:
                     name:University of Leeds
                     address:
                        name:Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK
                        type:PostalAddress
                     type:Organization
                     name:Leeds Teaching Hospitals NHS Trust
                     address:
                        name:NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Prevention of Rheumatoid Arthritis in At-Risk Individuals: Current Status and Future Prospects
      description:Early intervention has been the cornerstone of improving outcomes in patients with rheumatoid arthritis. Over the past decade, the boundaries have been pushed in an attempt to achieve effective prevention strategies in those who are at high risk of developing rheumatoid arthritis. Core risk factors including the presence of serum anti-citrullinated protein antibodies, arthralgia and subclinical inflammation on imaging are highly predictive of arthritis development. The influence of air pollution, diet and the role of microbiome on disease progression are less clear. In turn, therapeutic focus has shifted to an earlier pre-arthritis phase of the disease continuum where the clinically apparent arthritis may potentially be intercepted. Seven proof-of-concept interventional trials in at-risk individuals have been conducted so far. Whether true prevention of rheumatoid arthritis is possible remains elusive. Promising signals towards permanent disease modulation and improvement in symptom burden were seen with some immunomodulatory therapies, whilst others were unsuccessful. Long-term follow-up is required to ascertain a true effect. Looking forward, a better understanding of the natural history and underlying biological mechanisms of arthritis development and more accurate, validated risk stratification is needed.
      datePublished:2024-07-02T00:00:00Z
      dateModified:2024-07-02T00:00:00Z
      pageStart:895
      pageEnd:907
      sameAs:https://doi.org/10.1007/s40265-024-02061-0
      keywords:
         Pharmacotherapy
         Pharmacology/Toxicology
         Internal Medicine
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs40265-024-02061-0/MediaObjects/40265_2024_2061_Fig1_HTML.png
      isPartOf:
         name:Drugs
         issn:
            1179-1950
            0012-6667
         volumeNumber:84
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer International Publishing
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Task Toyoda
            url:http://orcid.org/0000-0001-5784-9281
            affiliation:
                  name:University of Leeds
                  address:
                     name:Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK
                     type:PostalAddress
                  type:Organization
                  name:Leeds Teaching Hospitals NHS Trust
                  address:
                     name:NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Kulveer Mankia
            affiliation:
                  name:University of Leeds
                  address:
                     name:Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK
                     type:PostalAddress
                  type:Organization
                  name:Leeds Teaching Hospitals NHS Trust
                  address:
                     name:NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Drugs
      issn:
         1179-1950
         0012-6667
      volumeNumber:84
Organization:
      name:Springer International Publishing
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:University of Leeds
      address:
         name:Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK
         type:PostalAddress
      name:Leeds Teaching Hospitals NHS Trust
      address:
         name:NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK
         type:PostalAddress
      name:University of Leeds
      address:
         name:Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK
         type:PostalAddress
      name:Leeds Teaching Hospitals NHS Trust
      address:
         name:NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Task Toyoda
      url:http://orcid.org/0000-0001-5784-9281
      affiliation:
            name:University of Leeds
            address:
               name:Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK
               type:PostalAddress
            type:Organization
            name:Leeds Teaching Hospitals NHS Trust
            address:
               name:NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK
               type:PostalAddress
            type:Organization
      name:Kulveer Mankia
      affiliation:
            name:University of Leeds
            address:
               name:Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK
               type:PostalAddress
            type:Organization
            name:Leeds Teaching Hospitals NHS Trust
            address:
               name:NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK
      name:NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK
      name:Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK
      name:NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(337)

Analytics and Tracking {📊}

  • Google Tag Manager

Libraries {📚}

  • Clipboard.js
  • Prism.js

Emails and Hosting {✉️}

Mail Servers:

  • mx.zoho.eu
  • mx2.zoho.eu
  • mx3.zoho.eu

Name Servers:

  • josh.ns.cloudflare.com
  • zita.ns.cloudflare.com

CDN Services {📦}

  • Crossref

5.67s.